



**GIG**  
CYMRU  
**NHS**  
WALES

Bwrdd Iechyd Prifysgol  
Bae Abertawe  
Swansea Bay University  
Health Board

Cadeirydd/Chair: **Emma Woollett**  
Prif Weithredwr/Chief Executive: **Mark Hackett**

**gofalu am ein gilydd, cydweithio, gwella bob amser**  
**caring for each other, working together, always improving**

Rydym yn croesawu gohebiaeth yn y Gymraeg ac yn y Saesneg. We welcome correspondence in Welsh or English.

Dyddiad/Date: 4<sup>th</sup> August 2021  
Ein Cyf / Our Ref: 21-G-020

☎ 01639 648363

✉ FOIA.Requests@wales.nhs.uk

[REDACTED]

Corporate Services  
Headquarters  
1 Talbot Gateway  
Baglan  
Port Talbot, SA12 7BR

[REDACTED]

I refer to your Freedom of Information Act Request acknowledged by ourselves on 19<sup>th</sup> July 2021. Your request sought information relating to Oesophageal Cancer.

Please note that we have provided this information for the period 01.01.21 to 30.06.21.

**1. Does your Health Board treat the following conditions?**

- **Advanced oesophageal cancer**  
Yes
- **Advanced gastric cancer**  
Yes
- **In case you do not treat either of the above conditions, which other trust do you refer these patients to?**  
Not applicable

**2. Please provide the total number of patients treated in the last 6 months for**

Please note that this question is answered from the perspective of new diagnoses receiving first definitive procedures only.

- **Oesophageal cancer (any type)**  
22
- **Oesophageal adenocarcinoma**  
12
- **Oesophageal squamous cell carcinoma**  
7



Pencadlys BIP Bae Abertawe, Un Porthfa Talbot, Port Talbot, SA12 7BR / Swansea Bay UHB Headquarters, One Talbot Gateway, Port Talbot, SA12 7BR

Bwrdd Iechyd Prifysgol Bae Abertawe yw enw gweithredu Bwrdd Iechyd Lleol Prifysgol Bae Abertawe  
Swansea Bay University Health Board is the operational name of Swansea Bay University Local Health Board

- **Unresectable oesophageal squamous cell carcinoma**  
<5
- **Gastric cancer (any type)**  
14
- **HER2 negative or HER2 untested gastric cancer**  
HER2 status is not a dataset item within our cancer database, therefore this information is not available.

**3. For oesophageal squamous cell carcinoma only, how many patients were treated in the past 6 months with:**

- **Platinum and Fluoropyrimidene based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)**  
5
- **Any other systemic anti-cancer therapy**  
7
- **Palliative care only**  
Not available from Chemocare

**4. For gastric cancer only, how many patients were treated in the past 6 months with:**

- **CapeOx (Capecitabine with Oxaliplatin)**  
0
- **FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)**  
0
- **Any other systemic anti-cancer therapy**  
7
- **Palliative care only**  
Not available from Chemocare

**5. Does your Health Board participate in any ongoing clinical trials for the treatment of oesophageal cancer? If so, can you please provide the name of each trial and the number of patients taking part?**

Yes

SCOPE2 - A randomised Phase II/III trial to study radiotherapy dose escalation in patients with oesophageal cancer treated with definitive chemo-radiation with an embedded Phase II trial for patients with a poor early response using positron emission tomography (PET)

<5 patients recruited in time period specified

**6. Does your Health Board participate in any ongoing clinical trials for the treatment of gastric cancer? If so, can you please provide the name of each trial and the number of patients taking part?**

Yes

Add-Aspirin - A phase III, double-blind, placebo-controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours.

No patients recruited in time period specified.



Where fewer than 5 has been indicated we are unable to provide you with the exact number of patients as due to the low numbers, there is a potential risk of identifying individuals if this was disclosed. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

I hope this information is helpful. If you require anything further please contact us at [FOIA.Requests@wales.nhs.uk](mailto:FOIA.Requests@wales.nhs.uk).

Under the terms of the Health Board's Freedom of Information policy, individuals seeking access to recorded information held by the Health Board are entitled to request internal review of the handling of their requests. If you would like to complain about the Health Board's handling of your request please contact me directly at the address below or register your complaint via [FOIA.Requests@wales.nhs.uk](mailto:FOIA.Requests@wales.nhs.uk).

If after Internal Review you remain dissatisfied you are also entitled to refer the matter to the information commissioner at the Information Commissioner's Office (Wales), 2<sup>nd</sup> Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH. Telephone Number: 029 2067 8400.

Yours sincerely



Pam Wenger  
**Director of Corporate Governance**

